Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:52:44.297Z.
Calculation as of: 2026-10-06T17:52:44.297Z.
Quote observation: 2026-10-06T17:49:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 444c4789ee5bc9aeb41ce43a5a9ac385aa2bf00f4834dff778c1621e598ef681
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Oramed Pharmaceuticals Inc.
Market Cap
$181.63M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$183.94M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$178.36M
EV/EBITDA Ratio
N/A
TTM Avg
0.27x
3Y Avg
0.27x
5Y Avg
0.27x
Market Cap
$175.46M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$188.72M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$172.51M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$172.29M
EV/EBITDA Ratio
136.44x
TTM Avg
155.63x
3Y Avg
70.41x
5Y Avg
70.41x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. (ORMP) | $181.63M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.78M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.94M | N/A | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $178.36M | N/A | 0.27x | 0.27x | 0.27x |
| Compass Therapeutics, Inc. (CMPX)vs › | $175.46M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $188.72M | N/A | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $172.51M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $172.29M | 136.44x | 155.63x | 70.41x | 70.41x |
| RxSight, Inc. (RXST)vs › | $191.67M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
